Subject: Guidelines for Audit of Remdesivir in COVID-19 Hospitals.


*********

The State is experiencing second wave of COVID-19 and as there is a rapid surge of COVID-19 positive cases, the demand for Remdesivir has increased in both Government and Private Health Care Institutions. The data on the consumption of Remdesivir by the hospitals treating COVID-19 patients has revealed that there is an indiscriminate use of Remdesivir in many hospitals. An optimal use of Remdesivir needs to be ensured both for a better healthcare of the patient as well as the curtailment of wastage of the drug.

The Clinical Expert Committee of Karnataka has laid down the guidelines for minimizing wastage and rational use of Remdesivir in health care facilities which is attached as Annexure.

It is the responsibility of the health team to judicially use the drug and the responsibility of the hospital administrators to monitor and audit its use. Each facility shall also form a Remdesivir Audit Committee and submit a report on the use of Remdesivir pre and post audit to the Expert Committees constituted by the
Order No. HFW 276 ACS 2020, dated 29.07.2020. Further, the Expert Committees shall review the action taken by the health care facilities in this regard.

All the healthcare facilities in Karnataka are hereby directed to follow the guidelines in letter and spirit and report compliance to the respective BBMP/District Level Expert Committees.

The district authorities are instructed to disseminate the guidelines to all the health care institutions and monitor the implementation for better utilization of Remdesivir.

Additional Chief Secretary to Government Health and Family Welfare Department

To:

1. The Chief Commissioner, BBMP
2. The Commissioner, Department of Health and Family Welfare, Bangalore.
3. The Mission Director, NHM Bangalore
4. The Special Commissioner, BBMP.
5. All the Deputy Commissioners in the State of Karnataka.
6. The Director, Department of Health and Family Welfare, Bangalore.
7. The Director, Department of Medical Education, Bangalore.
8. All Divisional / Joint Directors, Health and Family Welfare Department.
9. The Chief Health Officer, BBMP.
10. All the District Health Officers / District Surgeons / Administrative Medical Officers and Taluk Medical Officers and Medical Superintendents of all General Hospitals in Karnataka.

Copy for Kind Information to:

1. Chief Secretary, Government of Karnataka, Vidan Soudha, Bengaluru.
2. Principal Secretary Department of Medical Education, Bengaluru.
3. PS to Health and Medical Education Minister, Vidhan Soudha, Bengaluru.
Annexure

Guidelines for use of Injection Remdesivir in COVID-19 patients*

Emergency Use Authorization (EUA) UA/Off label use (based on limited available evidence and only in specific circumstances):

Remdesivir (EUA) may be considered ONLY in patients with:

- Moderate to severe disease (requiring SUPPLEMENTAL OXYGEN), AND
- No renal or hepatic dysfunction (eGFR <30 ml/min/m², AST/ALT >5 times ULN (Not an absolute contradiction), AND
- Who are within 10 days of onset of symptom/s.

Recommended dose: 200 mg IV on day 1 f/b 100 mg IV OD for next 4 days.

Not to be used in patients who are NOT on oxygen support or in home settings

Injection Remdesivir shall be used in the wards of Designated COVID-19 Health Centre (DCHC) and Designated COVID-19 hospital.

*****